Inhibikase Therapeutics, Inc. (IKT)
IKT moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How IKT actually reacts to news — the realized, point-in-time move the market made, measured across 244 labeled events over the last three years with zero look-ahead.
IKT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 232 |
| 30-min | 0.00% | 48% | 239 |
| 60-min | +0.02% | 52% | 244 |
| to close | 0.00% | 47% | 243 |
| Middle 50% of IKT reactions | -2.04% to +1.79% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 244 |
Half of all Inhibikase Therapeutics, Inc. news events land between -2.04% and +1.79% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IKT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | +0.24% | 50% | -0.21% |
| Coverage initiations | 17 | 0.00% | 18% | -1.51% |
| Rating reiterations | 13 | 0.00% | 46% | +2.10% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how IKT ranks against every other measured name →
That’s how IKT usually reacts — get an email when it moves on news →Email me when IKT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IKT's baseline. Nothing else.
Recent IKT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.00% | +0.00% | |
| Form 8-K Inhibikase Therapeutics, For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.82% | |
| Form 8-K Inhibikase Therapeutics, For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | -2.02% | -0.40% | |
| Form 10-Q Inhibikase Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.68% | +0.84% | |
| Form 8-K Inhibikase Therapeutics, For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +1.68% | +0.84% | |
| Form S-8 Inhibikase Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +1.68% | +0.84% | |
| Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity | Press release | GlobeNewswire | +1.68% | +0.84% | |
| Form 8-K Inhibikase Therapeutics, For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +2.26% | +3.17% | |
| Form 8-K Inhibikase Therapeutics, For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | +0.68% | +9.39% | |
| Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH | Press release | GlobeNewswire | +0.68% | +9.39% | |
| Form 8-K Inhibikase Therapeutics, For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | -4.27% | +0.00% | |
| Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility | Press release | GlobeNewswire | -4.27% | +0.00% | |
| Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.50% | -1.00% | |
| Form 8-K Inhibikase Therapeutics, For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -0.53% | +2.12% | |
| Form 10-Q Inhibikase Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.79% | +0.53% | |
| Form 8-K Inhibikase Therapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | +0.53% | |
| Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity | Press release | GlobeNewswire | +0.79% | +0.53% | |
| Form ARS Inhibikase Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.34% | +2.14% | |
| Form DEF 14A Inhibikase Therapeutics, For: Jun 26 | SEC filing · Form DEF | SEC EDGAR | +1.34% | +2.14% | |
| Form DEFA14A Inhibikase Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +1.34% | +2.14% | |
| Form PRE 14A Inhibikase Therapeutics, For: Jun 26 | SEC filing · Form PRE | SEC EDGAR | -1.64% | -6.70% | |
| Form 8-K Inhibikase Therapeutics, For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.44% | |
| Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension | Press release | GlobeNewswire | +0.00% | +2.03% | |
| Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.40% | +0.56% | |
| Form 10-K Inhibikase Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.42% | +1.82% | |
| Form 8-K Inhibikase Therapeutics, For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +2.42% | +1.82% | |
| Form S-8 Inhibikase Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +2.42% | +1.82% | |
| Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity | Press release | GlobeNewswire | +2.42% | +1.82% | |
| Form 8-K Inhibikase Therapeutics, For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.92% | |
| Form 8-K Inhibikase Therapeutics, For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.03% | |
| Form 8-K Inhibikase Therapeutics, For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | +3.23% | -3.87% | |
| Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension | Press release | GlobeNewswire | +3.23% | -3.87% | |
| Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | +3.23% | -3.87% | |
| Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | +3.23% | -3.87% | |
| Form 10-Q Inhibikase Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.66% | |
| Form 8-K Inhibikase Therapeutics, For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.66% | |
| Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity | Press release | GlobeNewswire | +0.00% | +0.66% | |
| Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer | Press release | GlobeNewswire | +10.12% | — | |
| Form 10-Q Inhibikase Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K Inhibikase Therapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K Inhibikase Therapeutics, For: Jun 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form EFFECT Inhibikase Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -1.23% | +19.63% | |
| Form S-3 Inhibikase Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +0.00% | |
| Form DEFA14A Inhibikase Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +2.37% | -2.10% | |
| Form 10-Q Inhibikase Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.69% | -1.93% | |
| Form 8-K Inhibikase Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +1.69% | -1.93% | |
| Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity | Press release | GlobeNewswire | +1.69% | -1.93% | |
| Form ARS Inhibikase Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -8.83% | +1.36% | |
| Form DEF 14A Inhibikase Therapeutics, For: Jun 27 | SEC filing · Form DEF | SEC EDGAR | -8.83% | +1.36% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IKT section they belong to.
Where else IKT is measured.
IKT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Inhibikase Therapeutics, Inc.'s median reaction calculated?
Every labeled IKT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 244 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of IKT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IKT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.